Skip to content
Recall Observatory FDA recall evidence

Exact FDA event identifier

Event 90659

1 recalled-product record grouped only because every row carries this exact official event ID.

Open FDA event record

Event summary

Timeline bucket
July 21, 2022
Product types
Drug
Classifications
Class I
Statuses
Terminated
Recalling firm wording
Ultra Supplement LLC

Dossier provenance

Source snapshots represented here

  • openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Complete imported group

Every recalled product in this event

1 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 1

SUSTANGO (Pendenadril Tytrate Blend) Capsules, 400 mg, 10-count blisters per carton, Formulated by: Male FX Labs, Bangor, ME, ASIN X0024468I9.

D-1350-2022
Recall number
D-1350-2022
Initiated
July 21, 2022
Classification
Class I
Status
Terminated
Recalling firm
Ultra Supplement LLC
Quantity
750 cartons

App-derived interpretation

Unknown reason.no_named_rule · v1.0.0
Marketed Without an Approved NDA/ANDA: Analytical testing showed the presence of tadalafil.

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Marketed Without an Approved NDA/ANDA: Analytical testing showed the presence of tadalafil.

Code information

Lot DAP272109, Exp: 4/1/2026

Distribution pattern

Product was distributed nationwide in the USA via Amazon Marketplace on www.amazon.com.